BusinessBeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017By Nasdaq OMXMay 8, 2017, 12:31 PM UTC
BusinessBeyondSpring Chief Medical Officer to Present at Three Prominent Industry Conferences in May 2017By Nasdaq OMXMay 8, 2017, 12:31 PM UTC
BusinessBeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia PreventionBy Nasdaq OMXApr 25, 2017, 12:32 PM UTC
BusinessBeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia PreventionBy Nasdaq OMXApr 25, 2017, 12:32 PM UTC
BusinessBeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia PreventionBy Nasdaq OMXApr 25, 2017, 12:32 PM UTC
BusinessBeyondSpring Chief Medical Offer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017By Nasdaq OMXMar 22, 2017, 12:30 PM UTC
BusinessBeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British ColumbiaBy Nasdaq OMXMar 20, 2017, 12:30 PM UTC
BusinessBeyondSpring Chief Medical Officer to Present Clinical Data for Lead Asset Plinabulin for Non-Small Cell Lung Cancer Treatment and Neutropenia Prevention at 2017 BIO Asia International Conference in TokyoBy Nasdaq OMXMar 14, 2017, 12:31 PM UTC
